Signaling Pathways That Drive ¹⁸F-FDG Accumulation in Cancer.

Abstract

¹⁸F-FDG measures glucose consumption and is an integral part of cancer management. Most cancer types upregulate their glucose consumption, yielding elevated ¹⁸F-FDG PET accumulation in those cancer cells. The biochemical pathway through which ¹⁸F-FDG accumulates in cancer cells is well established. However, beyond well-known regulators such as c-Myc, PI3K/PKB, and HIF1α, the proteins and signaling pathways that cancer cells modulate to activate the facilitated glucose transporters and hexokinase enzymes that drive elevated ¹⁸F-FDG accumulation are less well understood. Understanding these signaling pathways could yield additional biologic insights from ¹⁸F-FDG PET scans and could suggest new uses of ¹⁸F-FDG PET in the management of cancer. Work over the past 5 years, building on studies from years prior, has identified new proteins and signaling pathways that drive glucose consumption in cancer. Here, we review these recent studies and discuss current limitations to our understanding of glucose consumption in cancer.